A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis

Mult Scler Relat Disord. 2017 Oct:17:92-94. doi: 10.1016/j.msard.2017.07.001. Epub 2017 Jul 3.

Abstract

Teriflunomide is an oral therapy approved for relapsing forms of multiple sclerosis which has been shown to reduce relapse rate and disability progression. We report the case of a 54-year -old black woman with multiple sclerosis who developed follicular lymphoma after about 8 months of exposure to teriflunomide. Importantly, apart from age, the patient had none of the established risk factors for follicular lymphoma. Moreover, although this is the first published case of a lymphoma on teriflunomide, it is not the first confirmed case. Ten other cases have so far been reported to pharmacovigilance worldwide, and a further 82 with leflunomide. In conclusion, an association between teriflunomide and a higher risk of lymphoma cannot be ruled out.

Keywords: Adverse event; Cancer; Follicular lymphoma; Leflunomide; Malignancy; Teriflunomide.

Publication types

  • Case Reports

MeSH terms

  • Crotonates / adverse effects*
  • Female
  • Humans
  • Hydroxybutyrates
  • Lymphoma, Follicular / chemically induced
  • Lymphoma, Follicular / etiology*
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / complications*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Nitriles
  • Toluidines / adverse effects*

Substances

  • Crotonates
  • Hydroxybutyrates
  • Nitriles
  • Toluidines
  • teriflunomide